Welcome to our dedicated page for American Well SEC filings (Ticker: AMWL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for American Well Corporation (Amwell) (NYSE: AMWL) brings together the company’s official regulatory disclosures, as filed with the U.S. Securities and Exchange Commission. These documents provide detailed information on Amwell’s financial reporting, material agreements and other significant corporate events related to its digital care and technology-enabled healthcare platform.
Among the key filings are Form 8‑K current reports, which Amwell uses to announce material events. Recent 8‑K filings include disclosures of quarterly financial results, with earnings reports furnished as exhibits and details on investor conference calls and webcasts. Other 8‑K filings describe material definitive agreements, such as amendments and statements of work with Elevance Health under which Amwell operates the LiveHealth Online white‑label digital care platform and receives annual subscription fees and related service fees.
Filings also outline amendments to provider agreements involving Online Care Group, P.C., Amwell’s clinical partner, which maintains a 50‑state network of clinical professionals delivering digital care consultations via the LiveHealth Online platform. These documents specify contract terms, renewal provisions and termination rights, offering insight into how Amwell structures long‑term partnerships that support its technology-enabled care services.
On Stock Titan, investors can use AI-powered tools to read and interpret Amwell’s SEC filings more efficiently. AI summaries highlight the main points of lengthy documents, explain the implications of material agreements and clarify the context of earnings-related disclosures. Real-time updates from EDGAR ensure that new 8‑K filings and other reports appear promptly, while structured access to exhibits helps users locate information on subscription arrangements, provider networks and other aspects of Amwell’s business.
For anyone analyzing AMWL, this page serves as a focused entry point into Amwell’s regulatory history, combining raw SEC documents with AI-generated explanations that make complex legal and financial language easier to understand.
Form 144 notice from American Well Corporation (AMWL) shows a proposed sale of 13,593 common shares, with an aggregate market value of $98,549.25, to be sold approximately on 08/19/2025 on the NYSE through Morgan Stanley Smith Barney LLC. The shares were acquired as restricted stock units from the issuer on 06/18/2025 and the acquisition/payment date is listed as 06/18/2025. The filer reports no securities sold during the past three months. The form includes the standard representation that the selling person is not aware of any undisclosed material adverse information and references Rule 144 and Rule 10b5-1 considerations.
Roy Schoenberg, Executive Vice Chairman and Director of American Well Corporation (AMWL), was granted 25,000 restricted stock units (RSUs) on 08/13/2025. The RSUs vest in equal installments over three years from the grant date, with portions vesting on each of the first, second and third anniversaries. After giving effect to the reported grant and prior holdings (and adjusted for a 1-for-20 reverse stock split that took effect July 10, 2024), the reporting person beneficially owned 133,302 shares of Class A common stock. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Schoenberg on 08/14/2025.
Ido Schoenberg, Chairman and co-CEO of American Well Corp (AMWL), received a grant of 50,000 restricted stock units (RSUs) on 08/13/2025. The RSUs vest in equal installments over three years, with vesting on each of the first, second and third anniversaries of the grant date. After the reported transaction, the filing shows 114,250 shares of Class A common stock beneficially owned directly and an additional 136,891 shares of Class A common stock beneficially owned indirectly through his wife.
Selected financials (June 30, 2025)
Q2 revenue $70,898; three‑month net loss $19,531 (net loss attributable to American Well $19,696; EPS $(1.24)). Six months revenue $137,731; net loss $37,887 (attributable $38,400).
Balance sheet: cash and cash equivalents $219,072; total assets $388,656; total liabilities $94,083; total stockholders' equity $294,573; accumulated deficit $(2,004,326). Deferred revenue $43,259; transaction price allocated to remaining performance obligations $84,725 (71% expected in the 12 months ending June 30, 2026).
- Revenue mix: platform subscription $40,460; visits $22,752; other $7,686 (Q2).
- Divestiture: sale of APC business closed Jan 8, 2025; net proceeds reported $20,400 and a gain of $10,713 recognized in H1 2025.